Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
80 results about "Gpr119 agonist" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Oleoylethanolamide (OEA) is the most potent endogenous GPR119 agonist identified to date, and the compound's effects on feeding are mediated through this receptor. GPR119 receptors are proposed to play a role in glucose homeostasis through modulation of insulin secretion.
Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
InactiveUS20060154866A1Lower blood sugar levelsImprove the level ofOrganic active ingredientsSenses disorderGpr119 agonistG protein-coupled receptor
The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
Owner:ARENA PHARMA
Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
InactiveUS20070072803A1Lower blood sugar levelsImprove the level ofOrganic active ingredientsSenses disorderGpr119 agonistG protein-coupled receptor
Owner:ARENA PHARMA
Aryl gpr119 agonists and uses thereof
InactiveUS20110294836A1Increased insulin secretionDecreased blood levelBiocideOrganic chemistryDiseaseAryl
Aryl gpr119 agonists and uses thereof
Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control.
Owner:METABOLEX INC
Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
InactiveUS20070072804A1Lower blood sugar levelsImprove the level ofOrganic active ingredientsSenses disorderGpr119 agonistG protein-coupled receptor
Owner:ARENA PHARMA
Oxymethylene aryl compounds and uses thereof
InactiveUS20090270404A1Lowering plasma insulin levelGlucose degradationBiocideMetabolism disorderDiseaseAryl
Use of oxymethylene aryl GPR119 agonists and DPP IV inhibitors for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control are provided.
Owner:CYMABAY THERAPEUTICS
Cyclohexane analogues as gpr119 agonists
This invention relates to a series of substituted cyclohexane containing analogues which are agonists of GPR119 intended to treat metabolic diseases mediated by GPR119 including Type I & II diabetes mellitus. Diabetes mellitus is an ever-increasing threat to human health causing various complications (blindness, kidney failure, neuropathy, heart attack, stroke, etc.). Recently it was found that activation of GPR119 which is highly expressed in pancreatic beta cells causes glucose dependent insulin secretion and GLP-1 release. Many pharmaceuticals are currently developing GPR119 agonists and herein we disclose alternative GPR119 agonists. Our invention describes GPR119 agonists having structural Formula (I), pharmaceutically acceptable salt or solvate of Formula (I), isomer or prodrug of Formula (I), and combination therapy of Formula (I) with other anti-diabetic drugs like DPP-IV inhibitors and / or insulin sensitizers.
Owner:THE ASAN FOUND
GPR119 agonist and application thereof
The present invention discloses a GPR119 agonist, with a structural formula shown in a general formula (I). The present invention also provides methods for treating diseases with GPR119 as a treatment target, by administration of any pharmaceutically acceptable compound shown in the general formula (I), and the pharmaceutically acceptable salt of the compound; and method for treating or preventing metabolic disorders and obesity by administration of any pharmaceutically acceptable compound shown in the general formula (I), and the pharmaceutically acceptable salt of the compound.
Owner:BEIJING HANMI PHARMA CO LTD +1
Piperidine derivatives for Gpr119 agonist
The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.
Owner:CHONG KUN DONG CORP
Oxymethylene aryl compounds and uses thereof
InactiveCN102026636AMetabolism disorderHeterocyclic compound active ingredientsDiseaseGpr119 agonist
Owner:CYMABAY THERAPEUTICS
GPR119 agonist compounds
Owner:MANKIND PHARMA LTD
Novel compounds as gpr119 agonists
ActiveUS20170291910A1Significant glucose reductionIncreased insulin secretionOrganic active ingredientsOrganic chemistryGpr119 agonistCombinatorial chemistry
The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.
Owner:MANKIND PHARMA LTD
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
InactiveUS20140038889A1Increase secretionIncreasing blood incretin levelBiocideOrganic active ingredientsMeglitinideThiazolidinedione
The present invention relates to the GPR119 agonist, 1-methylcyclopropyl 4-(5-fluoro-6-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)pyrimidin-4-yloxy)piperidine-1-carboxylate (Compound 1): and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing the secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.
Owner:ARENA PHARMA
Compounds for the Treatment of Metabolic Disorders
InactiveUS20120059014A1Use of typeUseful in treatmentBiocideOrganic chemistryGpr119 agonistType ii diabetes
The present invention is directed to therapeutic compounds of the following formula (I)which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
Owner:PROSIDION LIMITED
Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
InactiveUS20100137293A1Lower blood sugar levelsImprove the level ofBiocideSenses disorderGpr119 agonistCombined Modality Therapy
The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.
Owner:ARENA PHARMA
Novel gpr119 agonist compounds
ActiveUS20170291894A1Reduce doseOrganic active ingredientsOrganic chemistryGpr119 agonistMedicinal chemistry
Owner:MANKIND PHARMA LTD
GPR 119 agonists
The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating one or both of diabetes and obesity using the compounds of the invention. The present invention is directed to G-protein coupled receptor (GPCR) agonists that are useful for the treatment of obesity, diabetes and related metabolic disorders.
Owner:CADILA HEALTHCARE LTD
GPR119 hydrazide agonist, preparation method and use thereof
The invention relates to the field of medicines related to type 2 diabetes, and in particular relates to a GPR119 agonist containing a hydrazide structure, and a preparation method and application thereof in preparation of a medicine for treating type 2 diabetes. The GPR119 agonist disclosed by the invention is represented by the formula shown in the specification, wherein R is selected from a group including H, C1-C3 alkyl and C3-C6 cycloalkyl.
Owner:FOSHAN SAIWEISI MEDICINE SCI & TECH
Substituted piperidinyl compounds useful as GPR119 agonists
Owner:MERCK SHARP & DOHME LLC
Pyrimidopyrimidine type derivative as well as preparation method and application thereof to medicines
The invention provides a pyrimidopyrimidine type derivative as well as a preparation method and application thereof to medicines. The invention relates to a novel pyrimidopyrimidine type derivative shown as a general formula I, a preparation method thereof and application of a pharmaceutical composition containing the derivative and pharmaceutically acceptable salt, which are used as a treatment agent, especially a GPR119 agonist, and to medicines for treating anti-diabetic and metabolic diseases and preventing diseases including metabolism disorder and obesity.
Owner:江西乐成生物科技有限公司
Compounds for the treatment of metabolic disorders
The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
Owner:PROSIDION LIMITED
Quinolinone derivative and preparation method and application thereof
ActiveCN104447693AAgonistic activityOrganic active ingredientsOrganic chemistryGpr119 agonistDrug biological activity
The invention provides a quinolinone derivative as shown in a general formula I and a preparation method thereof, wherein R indicates C1-C4 alkyl. The invention also provides application of the quinolinone derivative as a GPR119 excitant and in preparing a drug for treating diabetes. The compound provided by the invention has certain biological activity and most importantly, the compound provided by the invention is a novel GPR119 excitant with good physicochemical properties.
Owner:SUZHOU HIGHFINE BIOTECH
GPR119 agonist containing cyclopropyl hydrazide and halogenated benzene structures and application thereof
The invention relates to the field of medicines related to type II diabetes mellitus and in particular relates to a GPR119 agonist containing cyclopropyl hydrazide and halogenated benzene structures, a preparation method of the GPR119 agonist and application of the GPR119 agonist to preparation of medicines related to type II diabetes mellitus. The GPR119 agonist has a structure shown in a general formula in the specification, wherein in the general formula, X is selected from halogen substituent.
Owner:FOSHAN SAIWEISI MEDICINE SCI & TECH
Compounds for the treatment of metabolic disorders
Owner:PROSIDION LIMITED
Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists
ActiveUS8772323B2Shorten the progressImproving glycaemic controlBiocideOrganic chemistryGpr119 agonistBenzoxazole
The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
Owner:BOEHRINGER INGELHEIM INT GMBH
GPR119 agonist containing alkyl substituted benzenesulfonyl hydrazine as well as preparation method and application thereof
ActiveCN104610105AHigh activityMetabolism disorderSulfonic acid amide preparationGpr119 agonistMedicine
The invention relates to the field of medicines related to type II diabetes mellitus and in particular relates to a GPR119 agonist containing an alkyl substituted benzenesulfonyl hydrazine structure, a preparation method of the GPR119 agonist and application of the GPR119 agonist to preparation of medicines related to type II diabetes mellitus. The GPR119 agonist has a structure shown in a general formula in the specification, wherein in the general formula, R is selected from C1-C3 alkyl.
Owner:邳州市润宏实业有限公司
Derivative containing glucosamine and nitrile pyridine structure and use thereof
The invention relates to the field of drugs associated with Type II diabetes and particularly relates to a GPR119 agonist containing glucosamine and a nitrile pyridine structure shown in the specification as well as a preparation method thereof and an application of the GPR119 agonist in preparation of Type II diabetes drugs.
Owner:FOSHAN SAIWEISI MEDICINE SCI & TECH
Novel GPR 119 agonists
The present invention relates to novel GPR 119 agonists of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.
Owner:CADILA HEALTHCARE LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com